ROS1 Biomarkers
News and reporting on ROS1 biomarkers.
Turning Point Therapeutics' NDA Submission for Repotrectinib in Sight Based on Registrational Data
Based on positive data from the TRIDENT-1 trial, the firm will meet with the FDA to discuss its regulatory application in ROS1-positive advanced NSCLC.
Nuvalent Begins Study of ROS1 Inhibitor in Advanced NSCLC, Solid Tumors
The firm has designed the agent to overcome resistance to currently available ROS1 inhibitors and to treat cancers that have metastasized to the brain.
AnHeart Raises $61M in Oversubscribed Series B Financing Round
The firm will use the funds to advance its pipeline of next-generation precision oncology drugs, including taletrectinib in ROS1 and NTRK fusion-positive solid cancers.
AnHeart Therapeutics Begins Phase II Taletrectinib Study in ROS1 Fusion-Positive Lung Cancer
The trial will evaluate AnHeart's lead candidate taletrectinib in patients with NSCLC harboring a ROS1 fusion.
AnHeart Therapeutics Begins Phase II Basket Trial of Taletrectinib in NTRK-Positive Solid Tumors
AnHeart licensed taletrectinib this month to Innovent Biologics, which will codevelop and commercialize the drug in greater China.